Aerie Pharma (AERI) Confirms FDA Approval of Rhopressa 0.02% for Lowering of Elevated IOP in Patients with Open-Angle Glaucoma or Ocular Hypertension
Tweet Send to a Friend
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
